BUTAPERAZINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C24H31N3OS
Molecular Weight	409.587
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

CCCC(=O)C1=CC=C2SC3=C(C=CC=C3)N(CCCN4CCN(C)CC4)C2=C1

InChI

InChIKey=DVLBYTMYSMAKHP-UHFFFAOYSA-N

InChI=1S/C24H31N3OS/c1-3-7-22(28)19-10-11-24-21(18-19)27(20-8-4-5-9-23(20)29-24)13-6-12-26-16-14-25(2)15-17-26/h4-5,8-11,18H,3,6-7,12-17H2,1-2H3

HIDE SMILES / InChI

Molecular Formula	C24H31N3OS
Molecular Weight	409.587
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

Butaperazine is an antipsychotic phenothiazine. As shown in animal studies butaperazine increases striatal and mesolimbic dopamine turnover. Butaperazine is effective in the management of schizophrenia. Extrapyramidal symptoms and drowsiness are the most common adverse effects.

CNS Activity

Originator

Approval Year

Targets

Targets

Primary Target	Pharmacology	Condition	Potency
Monoamine oxidase 32	Inhibitor 8,297
Dopamine receptor 60	Antagonist 2,778

C_max

Value	Dose	Co-administered	Analyte	Population
211 ng/mL	30 mg single, oral		BUTAPERAZINE plasma	Homo sapiens

AUC

Value	Dose	Co-administered	Analyte	Population
1990 ng × h/mL	30 mg single, oral		BUTAPERAZINE plasma	Homo sapiens

T_1/2

Value	Dose	Co-administered	Analyte	Population
17 h	30 mg single, oral		BUTAPERAZINE plasma	Homo sapiens

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
		substrate 1,217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer

Drug as victim

Show entries

Target	Modality	Activity	Metabolite	Clinical evidence
CYP2D6 1,217	substrate 3,367	yes		yes (co-administration study)

Showing 1 to 1 of 1 entries

Previous1Next

Sourcing

Sourcing

Show entries

Vendor/Aggregator	ID	URL
001 Chemical	DY565660	https://www.001chemical.com/chem/653-03-2
ABI Chem	AC1L1ZXR
ABI Chem	AC1Q5GH2
BOC Sciences	653-03-2
Chemieliva Pharmaceutical Co., Ltd	PBCM1373136

Showing 1 to 5 of 16 entries

Previous1 2 3 4Next

PubMed

PubMed

Title	Date	PubMed
No data available in table

Substance Class	Chemical
Record UNII	TXP4T9106S
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

BUTAPERAZINE

Official Name

English

Butaperazine [WHO-DD]

Common Name

English

BUTAPERAZINE [HSDB]

Common Name

English

RIKER-595

Code

English

1-{10-[3-(4-Methyl-1-piperazinyl)propyl]phenothiazin-2-yl}-1-butanone

Systematic Name

English

Showing 1 to 5 of 13 entries

Previous1 2 3Next

Show entries

Classification Tree

Code System

Code

Phenothiazines with piperazine structure

WHO-VATC

QN05AB09

Phenothiazines with piperazine structure

WHO-ATC

N05AB09

Agent Affecting Nervous System

NCI_THESAURUS

C66884

Agent Affecting Nervous System

NCI_THESAURUS

C29710

Showing 1 to 4 of 4 entries

Previous1Next

Show entries

Code System

Code

Type

Description

EVMPD

SUB06007MIG

PRIMARY

MESH

C084595

PRIMARY

NCI_THESAURUS

C81090

PRIMARY

ECHA (EC/EINECS)

211-493-9

PRIMARY

FDA UNII

TXP4T9106S

PRIMARY

Showing 1 to 5 of 16 entries

Previous1 2 3 4Next

Show entries

Related Record

Type

Details


					22VUW43J2H

BUTAPERAZINE MALEATE

SALT/SOLVATE -> PARENT

Showing 1 to 1 of 1 entries

Previous1Next

Show entries

Related Record

Type

Details


					TXP4T9106S

BUTAPERAZINE

ACTIVE MOIETY

Showing 1 to 1 of 1 entries

Previous1Next

SMILES

InChI

CNS Activity

Originator

Approval Year

Targets

Cmax

AUC

T1/2

Overview

OverviewOther

Drug as victim

Sourcing

PubMed

C_max

T_1/2